Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly

Abstract

BackgroundThe long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower growth hormone (GH) levels in patients with acromegaly and may also induce pituitary tumor shrinkage.ObjectiveWe performed a meta-analysis to accurately assess the effect of octreotide on pituitary tumor shrinkage.Data SourcesA computerized Medline and Embase search was undertaken to identify potentially eligible studies.Study Eligibility CriteriaEligibility criteria included treatment with octreotide, availability of numerical metrics on tumor shrinkage and clear definition of a clinically relevant reduction in tumor size. Primary endpoints included the proportion of patients with tumor shrinkage and mean percentage reduction in tumor volume.Data Extraction and AnalysisThe electronic search identified 2202 articles. Of these, 41 studies fulfilling the eligibility criteria were selected for data extraction and analysis. In total, 1685 patients were included, ranging from 6 to 189 patients per trial. For the analysis of the effect of octreotide on pituitary tumor shrinkage a random effect model was used to account for differences in both effect size and sampling error.ResultsOctreotide was shown to induce tumor shrinkage in 53.0% [95% CI: 45.0%–61.0%] of treated patients. In patients treated with the LAR formulation of octreotide, this increased to 66.0%, [95% CI: 57.0%–74.0%). In the nine studies in which tumor shrinkage was quantified, the overall weighted mean percentage reduction in tumor size was 37.4% [95% CI: 22.4%–52.4%], rising to 50.6% [95% CI: 42.7%–58.4%] with octreotide LAR.LimitationsMost trials examined were open-label and had no control group.ConclusionsOctreotide LAR induces clinically relevant tumor shrinkage in more than half of patients with acromegaly.